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Abstract
Background: MDFT (Multidimensional Family Therapy) is a family based outpatient treatment programme for
adolescent problem behaviour. MDFT has been found effective in the USA in adolescent samples differing in
severity and treatment delivery settings. On request of five governments (Belgium, France, Germany, the
Netherlands, and Switzerland), MDFT has now been tested in the joint INCANT trial (International Cannabis Need of
Treatment) for applicability in Western Europe. In each of the five countries, study participants were recruited from
the local population of youth seeking or guided to treatment for, among other things, cannabis use disorder.
There is little information in the literature if these populations are comparable between sites/countries or not.
Therefore, we examined if the study samples enrolled in the five countries differed in baseline characteristics
regarding demographics, clinical profile, and treatment delivery setting.
Methods: INCANT was a multicentre phase III(b) randomized controlled trial with an open-label, parallel group
design. It compared MDFT with treatment as usual (TAU) at and across sites in Berlin, Brussels, Geneva, The Hague
and Paris.
Participants of INCANT were adolescents of either sex, from 13 through 18 years of age, with a cannabis use
disorder (dependence or abuse), and at least one parent willing to take part in the treatment. In total, 450 cases/
families were randomized (concealed) into INCANT.
Results: We collected data about adolescent and family demographics (age, gender, family composition, school,
work, friends, and leisure time). In addition, we gathered data about problem behaviour (substance use, alcohol
and cannabis use disorders, delinquency, psychiatric co-morbidity).
There were no major differences on any of these measures between the treatment conditions (MDFT and TAU) for
any of the sites. However, there were cross-site differences on many variables. Most of these could be explained by
variations in treatment culture, as reflected by referral policy, i.e., participants’ referral source. We distinguished ‘self-
determined’ referral (common in Brussels and Paris) and referral with some authority-related ‘external’ coercion
(common in Geneva and The Hague). The two referral types were more equally divided in Berlin. Many cross-site
baseline differences disappeared when we took referral source into account, but not all.
Conclusions: A multisite trial has the advantage of being efficient, but it also carries risks, the most important one
being lack of equivalence between local study populations. Our site populations differed in many respects. This is
not a problem for analyses and interpretations if the differences somehow can be accounted for. To a major
extent, this appeared possible in INCANT. The most important factor underlying the cross-site variations in baseline
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characteristics was referral source. Correcting for referral source made most differences disappear. Therefore, we will
use referral source as a covariate accounting for site differences in future INCANT outcome analyses.
Trial registration number: ISRCTN: ISRCTN51014277
Background
In 1999, the (junior) Ministers of Health of Belgium,
France, Germany, the Netherlands, and Switzerland
agreed that their countries were disputing each other’s
cannabis policies without having enough data to support
any stance. They wished to combine scientific efforts.
The Five-Countries Action Plan for Cannabis Research
from April 2003 stressed the need of a transnational trial
to test an outpatient treatment of cannabis use disorder
and associated problems (e.g., delinquency, psychiatric
co-morbidity) among youth in the five Western European
countries mentioned [1]. The treatment chosen for this
trial on the basis of its record of empirical support was
Multidimensional Family Therapy (MDFT), developed by
Liddle and colleagues at the Center for Treatment
Research on Adolescent Drug Abuse (CTRADA), Univer-
sity of Miami Miller School of Medicine [2]. The study
was named INCANT (INternational CAnnabis Need for
Treatment). It is a randomized controlled trial (RCT)
comparing MDFT with treatment as usual (TAU) at and
across sites in Berlin, Brussels, Geneva, The Hague and
Paris.
MDFT is a family based outpatient treatment pro-
gramme for adolescent problem behaviour [1 - 4]. Key to
MDFT is the assumption that each major domain in the
life of an adolescent may contribute to the incidence and
persistence of behavioural problems (through risk factors)
and may help in resolving such problems (through protec-
tive factors). The life domains include the youth itself,
parent, family, friends and peers, school and work, and lei-
sure time. In 5 to 7 months, the therapist carries out, in
rapid succession, therapy sessions with the adolescent
alone, with the parents alone, with the family (youth and
parents), and sometimes with representatives from systems
outside the family (friends, school, probation office, etc.)
present. The therapist sets out to improve life domain
conditions for the adolescent and the family in an out-
reaching fashion. MDFT views family functioning as
instrumental in creating new, developmentally adaptive
lifestyle alternatives for the adolescent. Skills training
includes substance use relapse prevention, family commu-
nication, and parenting.
MDFT has been tested with success in different ado-
lescent populations, doses and treatment delivery set-
tings in the USA [3,4].
Hurdles had to be overcome before the INCANT trial
could start. A RCT was controversial in Western Eur-
opean youth care at the time. It was feared that a
standardized (manual-based) time-limited treatment like
MDFT would not be accepted in France, with its domi-
nant psycho-analytic treatment tradition or in Germany
(Berlin), where treatment of substance abusing adoles-
cents often lasted for more than 1 year. Further, Swiss
clinicians believed that coercing adolescents into treat-
ment, which was deemed feasible in INCANT, would
fail to convince cases to accept or complete treatment.
Nevertheless, we managed to mount the INCANT study.
The process of randomization ensures that study
groups - i.e., the MDFT and TAU groups - are equivalent
on baseline characteristics. CONSORT, which is the opi-
nion leading Consolidated Standards of Reporting Trials
group, finds it illogical, but not wrong, to test for statisti-
cally significant differences between trial groups at base-
line, because by definition any difference found is due to
chance rather than the result of a factor causing variation
between groups (http://www.consort-statement.org).
However, this does not apply to multisite trials such as
INCANT. INCANT succeeded in randomizing study par-
ticipants on a number of stratification variables, but one
set of variables could not be included in the randomiza-
tion process: the local treatment culture in a city/country,
and the local referral and other treatment-related poli-
cies. Therefore, we performed statistical analyses to
assess the INCANT sites from the five countries on com-
parability of study participants’ baseline characteristics.
Issues like these increasingly turn up in the treatment
research literature, with its growing emphasis on ‘prac-
tice-relevant studies’. Relevance for practice means that
studies need to include sites with potentially different
ways of delivering services due to varying local or
national culture [5,6]. One of the primary methodological
challenges facing such multisite trials is how to deal with
site differences, and variability in treatment effects across
sites. In this paper, we follow well-grounded recommen-
dations from the literature for exploring baseline differ-
ences across sites in clinically-relevant background
characteristics, as well as in variables to be used for pri-
mary and secondary outcome analyses [7,8].
Methods
Study design
INCANT was a multicentre phase III(b) randomized con-
trolled trial with an open-label, parallel group design.
This study compared MDFT with TAU at and across
sites in Berlin, Brussels, Geneva, The Hague and Paris.
Part of TAU in Paris was specified in a treatment manual
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and was called TAU-e (e = explicit). In this paper, we
combine TAU-e and TAU under the term ‘TAU’; the
distinction between the two treatment variants will fea-
ture in other publications. Assessments were carried out
at baseline (immediately before randomization) and at 3,
6, 9 and 12 months after randomization. Before the trial
started, INCANT was approved by all relevant ethical
boards [1].
Treatment centres
On the basis of a pilot study testing the feasibility of
training European therapists in MDFT and the applic-
ability of MDFT in European practice, the following
treatment centres were selected for taking part in
INCANT [1]. In Belgium, the Cannabis Clinic associated
with the department of psychiatry of Brugmann Univer-
sity Hospital in Brussels was chosen, and in France the
Centre Emergence in Paris, with suburban CEDAT (Con-
seils Aide et Action contre le Toximanie) sub-sites in
Mantes la Jolie and St Germain en Laye. In Germany,
Therapieladen in Berlin was selected. The Netherlands
was represented by the twinning sites of Parnassia Brijder
(Mistral, youth addiction care) and De Jutters (Palmhuis,
youth forensic care) in The Hague. The Swiss site was
Phénix in Geneva.
Participants
Candidates for INCANT were adolescents of either sex,
from 13 through 18 years of age, with a cannabis use
disorder (dependence or abuse), and at least one parent
willing to take part in the treatment. The word ‘parent’
denotes any legal representative of the adolescent,
including step or foster parent, or guardian. We use the
singular ‘parent’ here, also including the plural ‘parents’.
Adolescents were ineligible if they had an IQ lower
than 70, or were unable to understand the local language,
unable to attend outpatient sessions, or if suffering from
a mental or behavioural disorder that required inpatient
treatment.
Power calculations
The government representatives of the five European
countries subsidizing the study requested INCANT to be
one transnational trial rather than a collection of five
local trials. The representatives wished to stimulate
across-border research collaboration. To render across-
site comparisons possible, each INCANT site adopted
the same study procedures (informed consent, measure-
ment instruments, assessments, etc.). A second reason
why we opted for the 1 joint trial model followed from
power calculations. According to our computations [1],
each site needed to recruit 100 cases for an effect size dif-
ference between MDFT and TAU of d = 0,7 and power
level of 0.82 (120 cases for power level 0.88). The Belgian
and Swiss governments did not have sufficient funds to
have 120 cases recruited in their countries. They settled
for N = 60 each, explicitly signing in on across-site statis-
tical analyses.
The recruitment target set for INCANT as a whole
was 450 cases (= adolescents and their families) [1].
Brussels and Geneva opted for N = 60 each, Berlin and
Paris for 120 each, and The Hague for 150.
Recruitment and randomization
Procedures for baseline assessments, recruitment and
concealed randomization have been described before [1].
Baseline assessments were conducted by research staff at
each site, who had been trained in adhering to the three
INCANT Instruction Manuals and whose performance
was monitored by Erasmus MC and discussed in joint
telephone meetings.
Randomization took place immediately after having
obtained informed consent, with equal portions to be
assigned to MDFT and TAU (1:1), except for Paris
where the ratio between MDFT and TAU (including
TAU-e) was roughly 1:2. In Berlin, Brussels, Geneva
and Paris, we stratified the local study sample using
three dichotomous variables (gender; age [13-14 years
vs. 15-18 years]; and level of cannabis use in the past 90
days [74 or fewer days of cannabis consumption vs. 75
or more]). In The Hague, we added the stratification
variable ‘ethnic background’ to the variables just men-
tioned. Across sites and sub-sites, there were 72 strata.
For each stratum, the database computer generated 50
independent randomisations.
All sites except Paris had two randomisation arms
(MDFT vs. TAU), and we used block randomisation
with randomly permuted blocks of 2 or 4 cases. For
Paris, with three randomisation arms, we used blocks of
3 or 6 cases.
Across sites, we assessed 721 families for eligibility for
the trial (Figure 1). Of these families, 271 (38%) were
excluded, for reasons explained below. Not in the figure
and not discussed here are 13 TAU cases in Paris who
were not randomized into the trial but did take part in
study surveys to learn more about TAU.
Baseline assessment was scheduled in two meetings,
allowing the family time to consider giving informed con-
sent in between the assessments. Cases were excluded if
they failed to show up for the second meeting (66 cases;
see Figure 1).
There were three other reasons for exclusion: (1) ado-
lescents appearing to have no recent diagnosis of canna-
bis use disorder as examined at the second meeting (16%
of all those assessed), (2) cases (adolescent and/or parent)
refusing to sign informed consent (6% of cases assessed),
and (3) ‘other reason’: these were mostly cases where the
referral agency refused to accept treatment allocation to
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be randomized, or where the youth disappeared from
sight before randomization occurred (e.g., because of
detention or moving away).
Among all youth assessed, there were 604 adolescents
with a cannabis use disorder. Of the latter group, 450
(75%) were enrolled in the study together with their
parents. Pre-set recruitment targets were attained in
Berlin, Brussels, Geneva and Paris. The Hague remained
under its recruitment target of 150, because of staff
health problems that prevented full operation for some
time.
The excluded cases were similar to the included ones
in age, gender and level of cannabis use (ps > 0.05).
Central database
Each site had one or two researchers authorized to
access their own site’s internet based location - part of
the Erasmus MC managed INCANT central database
[1]. Only the Erasmus MC database manager had full
access to all locations and was mandated to change
inputted data if so instructed by the project leader (HR)
on behalf of the international committee overseeing the
design and execution of the trial.
Measures
Measurement instruments were questionnaires and
structured interviews. They were applied at baseline and
at four follow-up assessment points [1].
Background and demographic information
The Parent and Adolescent Interviews [1] were used to col-
lect demographic data on gender, age and ethnicity, and on
family composition, history of family drug use and mental
health problems, adolescent substance use history and
court involvement, treatment history and service utiliza-
tion, school functioning, peer relationships, and pastime
activities.
Substance use
Youth were assessed for cannabis use and other sub-
stance use disorders in various ways. Most relevant here
is the Timeline Follow-Back method (TLFB; validated
for adolescents) [9]. The TLFB retrospectively recorded
daily cannabis use for the 90-day period before baseline
and other assessments, using a calendar and other mem-
ory prompts to stimulate recall.
Cannabis use and other substance use disorders were
assessed with the Adolescent Diagnostic Interview-Light
(ADI-Light; [1]). This brief structured, multi-axial inter-
view is based on DSM-IV criteria for substance use
disorders in adolescents.
Psychosocial functioning
We measured adolescents’ symptoms of internalizing
and externalizing disorders with the Youth Self Report
(YSR) scales for Anxiety/Affective problems and for
Aggression/Delinquency problems, respectively. The
YSR has been proven to be reliable and valid across lan-
guages and countries, both at total instrument level
[10,11] and at the level of the scales used in INCANT
[12 - 14]. For the same items, we also administered the
‘parent version’ of the YSR, i.e., the CBCL (Child Beha-
vior Checklist [15]).
Baseline measures also to be used as outcome measures
Most questionnaires and interviews were administered
at more than one, or even all all assessment points, but
in this paper we focus on the TLFB, YSR and CBCL.
Referral
We recorded by whom the case had been referred to the
INCANT site for treatment. We distinguished six refer-
ral routes, viz. (1) self-referral (the adolescent took the
initiative to contact the site him- or herself), (2) referral
by relatives, friends or acquaintances, (3) by school, (4)
by other treatment and care agencies, and (5) referral by
Justice (youth probation officer or appointed family
guardian, public prosecutor, court). When analyzing the
data, we noted that referral source could be dichoto-
mized into a binary variable distinguished by two classes
of referral, i.e., Self-Determined (SD) and Externally
Coerced (EC). Self-Determined is defined here as seek-
ing referral on one’s own accord or with some suppor-
tive (non-coercive) prompting by people from the
adolescent’s social environment. EC is any referral the
adolescent feels he or she cannot resist out of fear of
sanctions, such as being kicked out of something
(school, services, and programmes), being placed out of
home, or being detained or otherwise being sanctioned
by Justice authorities.
The scientific committee overseeing INCANT, the
IST, agreed on an algorithm to classify referral source as
SD or EC. SD were all cases that were ‘self-referred’ or
‘referred by relatives, friends, or acquaintances’. By defi-
nition, all Justice-related referrals were EC.
Assessed for eligibility (n = 721) 
Enrollment 
Randomized (n = 450) 
Excluded (n = 271) 
No cannabis disorder (n = 117) 
No informed consent (n = 42) 
No show-up (n = 66) 
Other reasons (n = 46) 
Allocated to MDFT (n = 212) 
Berlin (n = 59) 
Brussels (n= 30) 
Geneva (n = 30) 
The Hague (n = 55) 
Paris (n= 38) 
Allocated to TAU (TAU: n = 
210; TAU-e: n = 28) 
Berlin (n = 61) 
Brussels (n= 30) 
Geneva (n = 30) 
The Hague (n = 54) 
France (TAU: n= 35; 
 TAU-e: n = 28) 
Allocation 
Figure 1 INCANT recruitment flowchart.
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We decided to re-examine the cases referred by school
or by another treatment or care agency. In our algo-
rithm, referral by school was considered SD when refer-
ral carried no threat of the youth being sent away from
school if refusing to accept treatment. Referral by
another treatment or care agency was considered to be
EC when some sanction was pending if treatment was
refused. In The Hague, for instance, there were cases
where the adolescent had been mandated by Justice to a
mental health centre, which referred the adolescent on
to the INCANT site, but with the original legal threat
still lingering on (so, EC). Of the Berlin teenagers, one
in five lived in a residential setting, including sheltered
living (Betreutes Wohnen, i.e., the adolescent getting his
own apartment and some pocket money, with supervi-
sion from a social worker). The pressure put on the
adolescents in Betreutes Wohnen to seek help was con-
sidered EC.
For each ‘school referred’ and ‘other treatment and
care agency referred’ adolescent, we asked the local
researcher who had done the baseline assessment and
the therapist who had given the treatment, to classify
the case as SD or EC on the basis of the algorithm.
There were no differences in opinion. All cases could be
classified as either SD or EC. The project leader (HR)
reviewed all these cases and found no reason to ques-
tion the verdicts.
Analyses
In countries with more than 1 sub-site (France and the
Netherlands), we pooled the data at site level.
Analysis of Variance (ANOVA) was used to compare
the treatments on continuous variables such as level of
cannabis consumption, and c2 to compare them on
categorical variables such as gender. Post hoc compari-
sons for the significant ANOVA models were conducted
with the Tukey test. We also carried out a multivariate
analysis of variance (MANOVA) for three intended out-
come measures, using continuous data, pulled together.
Analyses were performed both across and within sites.
Within sites, there were no significant statistical differ-
ences between treatment groups, and these data are not
reported here (please contact the corresponding author
for these results if desired). The results from statistical
analyses reported below are from the cross-site analyses.
As missing data were rare at baseline (typically less
than 1% per item), they were handled with list-wise
deletion as proposed by Allison [16].
Results
Cross-site comparisons on the stratification variables
Were sites comparable on the stratification variables
(age, gender, and level of cannabis consumption) at
baseline? Table 1 presents an overview.
The average age of all INCANT adolescents was 16.3
years (standard deviation: 1.2), with no statistically sig-
nificant difference between sites. For stratification, we
distinguished a young age group (13 to 14 years of age)
and an older one (15 through 18). Roughly one out of
ten youth recruited were in the younger age category,
irrespective of site and treatment condition (Table 1).
Of all adolescents, 86% were boys. There was a slight
difference between sites, with Berlin and The Hague
having lower proportions of boys than the other sites
(c2 [4, 450] = 9.9, p = 0.04).
The TLFB was used to record days of cannabis con-
sumption in the 90 days before the baseline assessment.
Sites varied on the TLFB measure (ANOVA, F [4, 444]
= 4.2, p = 0.002), with participants in Geneva reporting
fewer days of cannabis use than participants in Brussels,
The Hague, and Paris.
Cross-site comparisons on other baseline characteristics:
adolescents
Table 2 lists a number of baseline characteristics on
which we compared treatment conditions. There were
no significant differences within sites. We focus here on
the comparisons between sites.
Demographics: living with family
The vast majority of adolescents were still living with
family, i.e., their parents or other relatives. Sites did not
differ in this respect.
Demographics: foreign descent
An adolescent was considered to be from foreign des-
cent if at least one of his or her parents had been born
abroad. Sites differed in the proportion of adolescents
with foreign background (c2 [4, 440] = 28.4, p < 0.001),
with the highest proportion seen in Geneva, followed by
The Hague (Table 2).
From which countries did the parent(s) of the youth
with foreign background come from? Most dominant in
Brussels were ‘other European country’ (55% of all those
with foreign descent) and ‘Africa’ excluding North
Africa (27%). For Paris, most prominent were ‘North
Africa’ (52%) and ‘other European country’ (29%). In
Berlin, ‘other European country’ (49%) prevailed among
the nations of origin, with ‘Turkey’ (17%) at second
place. The top two for The Hague were ‘Surinam/Dutch
Antilles’ (60%) and ‘North Africa’ (13%; in particular
Morocco). The sizable proportion of adolescents from
foreign descent in Geneva was mainly due to the high
prevalence of teenagers of ‘other European country’
background (90%).
Substance use: cannabis use disorder
The adolescent had to have a cannabis use disorder to
be eligible for the trial. Most youth qualified for the
diagnosis ‘cannabis dependence’ (84% across sites) and
the others (16%) for the diagnosis ‘cannabis abuse’.
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The rate of cannabis dependence differed between
sites (c2 [4, 450] = 20.6, p < 0.001), being lowest in The
Hague and Paris, where approximately 25% presented
with the milder diagnosis ‘abuse’.
Substance use: alcohol use disorder
Alcohol abuse and alcohol dependence are combined as
‘alcohol use disorders’ in Table 2. Sites varied in preva-
lence of alcohol use disorders (c2 [4, 450] = 68.0, p <
0.001). These disorders were common, except in The
Hague (16%) and Paris (30%).
Substance use: other drugs
Many adolescents had experience with other drugs, but
not on a regular basis. For no class of drugs other than
cannabis, substance use disorder rate exceeded the 5%
level at any site.
Other problem behaviour: legal problems
Across sites, 34% of the adolescents had been arrested
once or more in the 90 days preceding the baseline
assessment (Table 2). Sites differed on this measure (c2
[4, 447] = 22.7, p < 0.001), with arrest rate being lowest
in Berlin (20%) and The Hague (28%) and highest in
Geneva (50%).
More than one reason of arrest could be listed per
case. Arrests were mostly for drug offenses, property
crimes and violence, but this differed between sites. Of
the arrested youth in Brussels, 23% were charged for a
drug offense and in Paris and Geneva close to 40%. The
figure for Berlin was 8% and for The Hague 1%. Other
reasons of arrest varied between sites as well. Of Swiss
arrested adolescents, 30% had been booked for property
crimes, as compared with approximately 10% of Belgian,
German and Dutch teenagers, and with a low of 2% in
Paris. Violent crimes accounted for 8% - 20% of adoles-
cents who had been arrested, with Paris again being the
lowest ranking site (2%).
Risk factor: mental and behavioural co-morbidity
Co-morbidity is a risk factor for substance use disorders
and other problem behaviours [17]. Sites varied in ado-
lescent YSR self-report of externalizing (aggression and
delinquent behaviour) but not clearly in internalizing
problems (anxiety and depression). Externalizing pro-
blems: F [4, 425] = 6.4, p < 0.001. Internalizing pro-
blems: ANOVA, F [4, 425] = 2.3, p = 0.06. Youth in
Berlin reported higher levels of externalizing symptoms
than youth in The Hague and Paris, and youth in Gen-
eva reported higher levels than youth in Paris (Table 2).
Most adolescents had not received any mental health
or behavioural treatment or other professional interven-
tion in the 90 days before baseline assessment. The sites
did not differ on this measure.
Social risk factors
Social risk factors influencing substance misuse and
other problem behaviour are hanging out with antisocial
rather than with pro-social peers, and poor rooting in
school or work [17].
Across sites, 88% of the adolescents said they had one
or more friends with a drug problem (ranging from 79%
in Berlin to 99% in The Hague (c2 [4, 449] = 23.5, p <
Table 1 Scores on stratification variables by treatment condition and site
Variable Brussels Paris Berlin The Hague Geneva
MDFT TAU MDFT TAU MDFT TAU MDFT TAU MDFT TAU
Aged 13 - 14 years 3% 3% 11% 5% 10% 12% 11% 9% 10% 10%
Male gender 93% 93% 92% 86% 81% 84% 80% 80% 90% 93%
Mean number of days of cannabis use 68
(21)
67
(23)
60
(25)
63
(27)
58
(28)
62
(24)
64
(23)
61
(24)
47
(25)
52
(29)
Figures between brackets = standard deviations
Table 2 Baseline characteristics of INCANT adolescents by site and treatment condition
Variable Brussels Paris Berlin The Hague Geneva
MDFT TAU MDFT TAU MDFT TAU MDFT TAU MDFT TAU
Living with family 97% 96% 100% 100% 79% 68% 98% 98% 82% 83%
Foreign descent 47% 27% 32% 34% 33% 25% 46% 48% 73% 60%
Cannabis dependence 97% 93% 79% 75% 86% 89% 73% 78% 90% 97%
Alcohol use disorder 67% 50% 34% 27% 66% 53% 18% 13% 57% 67%
Arrested in past 90 days 43% 40% 37% 44% 17% 23% 26% 30% 53% 47%
Mean internalizing symptoms 16.6
(8.0)
12.3
(6.9)
12.2
(10.5)
13.9
9.6)
16.3
(9.8)
17.3
(10.8)
14.1
(10.5)
13.7
(9.2)
13.0
(8.3)
14.4
(9.3)
Mean externalizing symptoms 23.1
(8.3)
19.4
(6.9)
19.4
(10.9)
17.3
(7.7)
23.8
(7.9)
22.5
(8.6)
19.7
(9.3)
17.6
(7.8)
21.7
(9.4)
22.7
(8.8)
In school 80% 80% 84% 89% 66% 67% 77% 74% 67% 70%
Employment (regular + temporary jobs) 63% 73% 14% 5% 21% 17% 62% 65% 26% 31%
Figures between brackets = standard deviations
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0.001). Contact with alcohol misusing peers also varied
between sites (c2 [4, 449] = 68.1, p < 0.001), and was
most frequent in The Hague (99%) and lowest in Brus-
sels (52%). Having delinquent friends was highest in The
Hague (95%) and lowest in Paris (62%), with a signifi-
cant difference across sites (c2 [4, 449] = 37.1, p < 0.001).
Most adolescents were still in school (Table 2), though
more so in Brussels and Paris than at the other sites (c2
[4, 446] = 14.7, p = 0.005). Lower and middle education
prevailed in Berlin (56%), Brussels (63%), The Hague
(70%), and Paris (63%). This figure was lowest in Geneva
(47%).
Having a job and pursuing employment varied across
sites. We took together the youth with a regular and with
a temporary job (Table 2). Sites differed on this com-
bined measure (c2 [8, 438] = 158.4, p < 0.001), with those
having paid work (mostly jobs on the side) being most
prevalent in Brussels and The Hague and least in Paris.
Of the French adolescents, 91% said they were not look-
ing for paid work - much more than at the other sites.
The Hague scored lowest on this measure, with 18%.
Cross-site comparisons on other baseline characteristics:
parents
Parents of 39% of all families were still together, but
most so in Paris (53% of families) and least in Berlin
(28%) (c2 [4, 446] = 18.1, p = 0.02). Table 3 shows the
mirror image, i.e., the proportion of parents who were
separated or divorced - lowest in Paris and highest in
Berlin.
We asked the adolescents to report on problems
experienced by their parents and siblings. Overall, about
30% of the youth stated that one or both parents had
mental health or addiction problems, with the highest
proportion being noted in Berlin (41%) and the lowest
in Paris (17%). Alcohol problems were the most preva-
lent of the three issues surveyed (alcohol, drugs, and
mental health). The parent having the problem differed
across sites, with fathers being more prevalent as ‘pro-
blem owner’ in Brussels, Geneva, and The Hague, and
mothers in Berlin and Paris. A smaller proportion of
parents reportedly had a history of legal problems
(14%), with Paris at the bottom of the list (5%). Parents
with a history of legal problems significantly differed
across sites (c2 [4, 450] = 16.0, p = 0.003).
As to parent reports of the problems of their children,
sites differed on the scores for both internalizing and
externalizing symptoms. Internalizing CBCL: F [4, 428]
= 3.9, p = 0.005. Externalizing CBCL: F [4, 429] = 4.24,
p = 0.002. Parents of French youth reported significantly
lower levels of externalizing symptoms for their children
than parents of Swiss youth, and parents of Dutch youth
reported lower levels of internalizing symptoms than
parents of German youth.
Explaining differences between sites: referral source
One would expect randomization to render study condi-
tions comparable on baseline characteristics except for
some chance variation. Indeed, this is the case in most
single-site trials. However, in multisite trials participant
demographics and clinical characteristics, as well as
treatment effectiveness, may vary across sites [7,8]. In
INCANT too, we saw cross-site differences in baseline
demographic and clinical characteristics, though not
between treatment conditions. We now turn to attempts
we made to account for these cross-site differences.
The general treatment culture varies between the five
INCANT countries because of differences in norms,
social structures, and local and national policies. Such
differences will not disappear through randomization.
We assumed that ‘referral source’ might be a good
proxy for the factors underlying heterogeneity between
sites.
As seen in Table 4 referral source varied across sites
(c2 [16, 450] = 466.5, p < 0.001). Self-referral and refer-
ral by family and friends were more common in Brussels
and Paris than in Berlin and The Hague, where referral
by other treatment and care agencies carried more
weight, and in Geneva with its high proportion of refer-
ral by Justice-related institutions.
Coercion
In Table 5 referral source has been classified as either
Self-Determined (SD) or Externally Coerced (EC).
Across sites, 49% of referrals were SD and 51% EC. SD
dominated in Brussels and Paris, but not in The Hague
and Geneva, where EC prevailed. In Berlin, SD and EC
matched each other in frequency. The across-sites dif-
ferences were statistically significant (c2 [4, 450] =
167.1, p < 0.001).
Referral source and SD/EC distinction were similar
for treatment conditions (MDFT and TAU) at all sites
(p > 0.7).
When referral source was taken into account, quite a
few initial differences in the baseline variables to be
used as outcome measures (substance use, alcohol use
disorder, co-morbid internalizing mental health symp-
toms) and in demographic characteristics (type of school
attended) were no longer significant.
However, accounting for referral source did not fully
redress differences in adolescent reports of externalizing
symptoms (F [4, 430] = 2.6, p = 0.04). Berlin youth
reported more externalizing symptoms than youth in
The Hague and Paris did, and youth in Geneva reported
more than youth in Paris.
We also performed a multivariate analysis of variance
(MANOVA) for three intended outcome measures
(TLFB, YSR, and CBCL) together, to examine the extent
to which referral source accounted for site differences
when considering variables combined. The result of the
Phan et al. BMC Psychiatry 2011, 11:110
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multivariate test was significant (F [20, 1350] = 1.77, p =
0.02). Subsequent univariate tests showed that, in addi-
tion to the variable ‘externalizing symptoms’ just men-
tioned, sites also differed in frequency of adolescent
substance use (F [4, 411] = 2.76, p = 0.03) when the
TLFB, YSR and CBCL measures were considered
together, with Swiss youth reporting significantly less
substance use than adolescents at the other sites.
Discussion and Conclusion
INCANT is a transnational trial involving sites in Berlin,
Brussels, Geneva, The Hague and Paris. Within sites,
MDFT and TAU groups were similar on virtually all
baseline characteristics studied, including stratification
variables and referral source. In contrast, baseline char-
acteristics of the participants substantially differed across
INCANT sites.
Referral source
In major part, the between-sites differences could be
explained by referral policy. In Brussels and Paris, most
adolescents sought treatment themselves or through
some non-coercive encouragement by family, friends or
sometimes school, whereas referral was more coercive
in Berlin and even more so in Geneva and The Hague.
When correcting for self-determined or coercive nature
of referral, most between-site differences disappeared.
Why did referral type differ? This was partly due to the
selection of sites. For instance, we wanted to have a site
in the inner-city of Paris. But there, families are affluent,
housing is expensive - to such extent that it protects
against divorce of parents -, and schools are so strict that
pupils are being sent off if failing one class. Under those
circumstances, youth have school-related and other
personal motives to seek help. In Brussels, there was no
professional referral to adolescent substance use treat-
ment to speak off when we started INCANT. So, the Bel-
gians advertised treatment through media channels,
resulting in a high rate of self- or family-referral. In
Berlin, INCANT site Therapieladen reinforced its net-
work of local treatment and care agencies. Here, many
referrals were from sheltered living facilities (Betreutes
Wohnen). In Geneva and The Hague, detention and
other justice-imposed measures are common and this
was reflected in a higher rate of coerced referral. This is
not to say that, for instance, the Dutch adolescents were
more delinquent or more strongly disordered than at the
other sites. Detaining youth is much more common in
the Netherlands (and Switzerland) than in the other
INCANT countries [18]. The dominant presence of jus-
tice-related authorities dictates referral practice.
Profiles
Study site populations were similar in many respects,
but nevertheless had distinct profiles. Take the example
of The Hague. The Dutch teenagers more often had
friends with a substance use or criminal behaviour pro-
blems than at the other sites. Still, when examining
overall clinical severity, the Dutch adolescents were not
as impaired as youth at some other sites. The rate of
cannabis dependence and the rate of alcohol use disor-
ders were lowest in The Hague and Paris. The frequency
Table 3 Baseline data about and provided by parents by site and treatment condition
Variable Brussels Paris Berlin The Hague Geneva
MDFT TAU MDFT TAU MDFT TAU MDFT TAU MDFT TAU
Parents divorced/
separated
50% 63% 47% 35% 71% 59% 60% 56% 63% 53%
Parents with substance use/mental problems 27% 33% 16% 18% 47% 36% 29% 26% 33% 33%
Parents with legal problems 27% 27% 5% 5% 16% 16% 14% 11% 10% 13%
Mean internalizing symptoms 22.1
(11.7)
22.0
(12.6)
17.7
(8.3)
20.3
(11.3)
22.0
(10.9)
23.5
(10.3)
17.7
(9.5)
18.1
(10.6)
21.8
(10.4)
21.9
(11.5)
Mean externalizing symptoms 27.4
(10.3)
25.8
(10.7)
23.3
(9.6)
20.6
(10.6)
27.3
(12.7)
25.6
(10.9)
24.6
(12.8)
22.4
(11.8)
29.5
(13.1)
26.8
(13.4)
Figures between brackets = standard deviations
Table 4 Source of referral of adolescents per site
Site Self-referred Relatives, friends School Treatment and care agencies Justice
Brussels 5% 62% 3% 7% 23%
Paris 14% 59% 10% 11% 6%
Berlin 5% 17% 1% 75% 2%
The Hague 2% 6% 0% 73% 19%
Geneva 2% 16% 2% 8% 72%
TOTAL 6% 30% 3% 42% 19%
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of self-reported internalizing and externalizing symp-
toms, as well as arrest rates, were also low. Most Dutch
teenagers had an income from a job or other employ-
ment, which may have kept them engaged in activities
that competed with time that could otherwise have been
spent using drugs or associating with delinquent peers.
The adolescent study population in Paris also presented
with less impairment than youth in Berlin, Geneva, and
Brussels. Cannabis dependence and alcohol use disorder
rates were relatively low among French youth, as were
the rates of externalizing symptoms and arrests. Most
teenagers of the Paris site were not looking for work, but
were well provided for by their affluent families.
The populations in Berlin, Brussels and Geneva scored
higher than those from The Hague and Paris on canna-
bis dependence, alcohol use disorders, and externalizing
symptoms. Parent divorce/separation rate was highest in
Berlin; the proportion of parents with legal problems
was highest in Brussels. Recent justice involvement was
highest among Geneva youth.
Sites are not the same as countries
We compared sites from five European countries. The
data collected pertain to these sites, but not necessarily
to the country where a site was located. What is true in
Berlin or Paris, for instance, may not be true in all of
Germany or France, respectively. A city does not repre-
sent the countryside. One site in a (semi-)federal state,
such as Belgium, Germany and Switzerland, does not
stand for the country as a whole. Therefore, all conclu-
sions in this paper are restricted to the sites selected for
INCANT, so do not extend to other sites.
The demands of a multisite trial
When five European governments are interested in hav-
ing a treatment tested for adolescents with cannabis use
disorder, as in our case, it would not be efficient to carry
out five separate trials. A multisite trial has the advantage
of having increased statistical power, and of being more
relevant for practice (external validity) than a stringently
controlled local trial would be. However, a multisite trial
also carries risks, the most important one being lack of
equivalence between local study populations. Our site
populations differed in many respects.
Variations between local study populations are not an
insurmountable barrier for pooling data across sites, if
they somehow can be accounted for [7,8]. This appeared
to be possible in INCANT. The major explanation of
the cross-site variations in baseline characteristics was
referral source. Correcting for referral source made
most differences disappear. Therefore, we will use refer-
ral source as covariate in future cross-site INCANT out-
come analyses.
An alternative approach for dealing with multisite
issues may be treating site as a random effect (i.e., a var-
iance component accounting for cross-site variation in
outcome [19]). However, this would require a larger
number of study sites than the five in INCANT [20].
Our experience with a transnational trial in an area
with such a limited history of experimental studies was
satisfactory. It appeared possible to include sites from dif-
ferent European countries, with different treatment sys-
tems and policies, into one meaningful cross-national
RCT. We gained more insight into the applicability of
MDFT in practice than would have been possible in
stand-alone studies. As next papers will show, the cross-
national study design did not stand in the way of demon-
strating the effectiveness of MDFT; on the contrary. Mul-
tisite trials are a recommendable option, provided each
site recruits a sufficient number of cases to allow for
local analyses if sites appear to differ on unexplainable
grounds.
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